Annie Zhang

1.1k total citations
57 papers, 719 citations indexed

About

Annie Zhang is a scholar working on Pathology and Forensic Medicine, Dermatology and Immunology and Allergy. According to data from OpenAlex, Annie Zhang has authored 57 papers receiving a total of 719 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pathology and Forensic Medicine, 19 papers in Dermatology and 11 papers in Immunology and Allergy. Recurrent topics in Annie Zhang's work include Multiple Sclerosis Research Studies (24 papers), Dermatology and Skin Diseases (19 papers) and Allergic Rhinitis and Sensitization (9 papers). Annie Zhang is often cited by papers focused on Multiple Sclerosis Research Studies (24 papers), Dermatology and Skin Diseases (19 papers) and Allergic Rhinitis and Sensitization (9 papers). Annie Zhang collaborates with scholars based in United States, Germany and United Kingdom. Annie Zhang's co-authors include James Richard, Robert J. Fox, Ralf Gold, J. Theodore Phillips, Gavin Giovannoni, Ludwig Kappos, Conor O’Kane, Sara Walton, Jing L. Marantz and Laura J. Balcer and has published in prestigious journals such as PLoS ONE, Neurology and Journal of Allergy and Clinical Immunology.

In The Last Decade

Annie Zhang

50 papers receiving 699 citations

Peers

Countries citing papers authored by Annie Zhang

Since Specialization

Citations

This map shows the geographic impact of Annie Zhang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Annie Zhang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Annie Zhang more than expected).

Fields of papers citing papers by Annie Zhang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Annie Zhang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Annie Zhang. The network helps show where Annie Zhang may publish in the future.

Co-authorship network of co-authors of Annie Zhang

This figure shows the co-authorship network connecting the top 25 collaborators of Annie Zhang. A scholar is included among the top collaborators of Annie Zhang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Annie Zhang. Annie Zhang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	51363 Growth Analysis in Children Aged Less Than 12 Years with Moderate-to-Severe Atopic Dermatitis 2024 ·Journal of the American Academy of Dermatology ·Amy S. Paller, Bob Geng, Alan D. Irvine, Elaine C. Siegfried, Michael J. Cork, Michele Ramien, Lawrence F. Eichenfield, Rajan Gupta, Bryan Adams, Marius Ardeleanu, Annie Zhang	1
2	43740 The Effect of Systemic Treatment on Different Anatomical Regions in Pediatric Patients with Atopic Dermatitis: Real-World Data from PEDISTAD 2023 ·Journal of the American Academy of Dermatology ·Danielle Marcoux, Michele Ramien, Martti Antila, Nelson Augusto Rosário Filho, Lara Wine Lee, (unknown), Joel C. Joyce, Rajan Gupta, Marius Ardeleanu, Annie Zhang	0
3	Type 2 cytokines sensitize human sensory neurons to itch-associated stimuli 2023 ·Frontiers in Molecular Neuroscience ·Madison R. Mack, Yannick Miron, (unknown), Paul E. Miller, Annie Zhang, Andrew Korotzer, (unknown), Paul Bryce	19
4	Dupilumab Provides Clinically Meaningful Responses in Children Aged 6–11 Years with Severe Atopic Dermatitis: Post Hoc Analysis Results from a Phase III Trial 2023 ·American Journal of Clinical Dermatology ·Elaine C. Siegfried, Michael J. Cork, Norito Katoh, Haixin Zhang, Chien‐Chia Chuang, (unknown), Ana B. Rossi, Sonya Cyr, Annie Zhang	8
5	Dupilumab significantly improves skin barrier function in patients with moderate‐to‐severe atopic dermatitis 2022 ·Allergy ·Evgeny Berdyshev, Elena Goleva, Robert Bissonnette, Irina Bronova, (unknown), Brittany Richers, (unknown), Marco Ramírez-Gama, Patricia A. Taylor, Amy Praestgaard, Inoncent Agueusop, (unknown), Mark Boguniewicz, Noah A. Levit, Ana B. Rossi, Annie Zhang, Donald Y.M. Leung	77
6	Disease characteristics, comorbidities, treatment patterns and quality of life impact in children <12 years old with atopic dermatitis: Interim results from the PEDISTAD Real-World Registry 2022 ·Journal of the American Academy of Dermatology ·Amy S. Paller, Emma Guttman‐Yassky, Marie L. A. Schuttelaar, Alan D. Irvine, Eulàlia Baselga, Yoko Kataoka, Martti Antila, Marjolein de Bruin‐Weller, Danielle Marcoux, (unknown), E. Rizova, Chunyuan Liu, Annie Zhang	10
7	Dupilumab with Topical Corticosteroids Provides Rapid and Sustained Improvement in Adults with Moderate-to-Severe Atopic Dermatitis Across Anatomic Regions Over 52 Weeks 2021 ·Dermatology and Therapy ·Andrew Blauvelt, Marjolein de Bruin‐Weller, Eric L. Simpson, Zhen Chen, Annie Zhang, Brad Shumel	12
8	Protocol for a prospective, observational, longitudinal study in paediatric patients with moderate-to-severe atopic dermatitis (PEDISTAD): study objectives, design and methodology 2020 ·BMJ Open ·Amy S. Paller, Emma Guttman‐Yassky, Alan D. Irvine, Eulàlia Baselga, Marjolein de Bruin‐Weller, Shyamalie Jayawardena, Annie Zhang, Paola Mina‐Osorio, E. Rizova, Zafer E. Ozturk	8
9	Number Needed to Treat in Multiple Sclerosis Clinical Trials 2017 ·Neurology and Therapy ·(unknown), Annie Zhang, Amy Pace, Karl E. Peace	4
10	Longer-Term Follow-Up of the Efficacy of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: Integrated Analysis of DEFINE, CONFIRM, and ENDORSE (P3.033) 2016 ·Neurology ·Ralf Gold, Gavin Giovannoni, J. Theodore Phillips, Robert J. Fox, Annie Zhang, C. C. W. Taylor, Jing L. Marantz	1
11	Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing–Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies 2016 ·Neurology and Therapy ·Ralf Gold, Gavin Giovannoni, J. Theodore Phillips, Robert J. Fox, Annie Zhang, Jing L. Marantz	25
12	Differential Recovery from Relapse Between Treatment Groups in the CONFIRM Study of Delayed-Release Dimethyl Fumarate (P7.215) 2015 ·Neurology ·Andrew Chan, J. Theodore Phillips, Robert J. Fox, Annie Zhang, James Potts, Nuwan Kurukulasuriya	1
13	Clinical Efficacy of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Relapsing-Remitting Multiple Sclerosis Patients with Highly Active Disease: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies (P7.228) 2015 ·Neurology ·J. Theodore Phillips, Ralf Gold, Gavin Giovannoni, Robert J. Fox, Annie Zhang, Nuwan Kurukulasuriya	2
14	Sustained Low Rate of Brain Volume Loss under Long-term Delayed-Release Dimethyl Fumarate Treatment in Relapsing-Remitting Multiple Sclerosis Patients: Results from the ENDORSE Study (P7.243) 2015 ·Neurology ·Ludwig Kappos, Robert J. Fox, Ralf Gold, Douglas L. Arnold, James Potts, Annie Zhang, Nuwan Kurukulasuriya	1
15	Anti-JC Virus Antibody Prevalence in Canadian MS Patients 2014 ·Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques ·Virender Bhan, Yves Lapierre, Mark S. Freedman, Pierre Duquette, Daniel Selchen, (unknown), L. A. van der Walt, Annie Zhang	16
16	BG-12 (Dimethyl Fumarate) Treatment for Relapsing–Remitting Multiple Sclerosis (RRMS) Increases the Proportion of Patients Free of Measured Clinical and Neuroradiologic Disease Activity in the Phase 3 Studies (P07.106) 2013 ·Neurology ·Eva Havrdová, Ralf Gold, Robert J. Fox, Ludwig Kappos, (unknown), Annie Zhang, Nuwan Kurukulasuriya, (unknown), Vissia Viglietta, (unknown), Gavin Giovannoni	1
17	Comparison of Patients Treated with Natalizumab and Interferon-beta/Glatiramer Using Propensity-Matched Multiple Sclerosis Registry Data (P01.211) 2013 ·Neurology ·Timothy Spelman, Fabio Pellegrini, Annie Zhang, Robert Hyde, Amy Pace, Shibeshih Belachew, María Trojano, Heinz Wiendl, Ludwig Kappos, Freek Verheul, François Grand’Maison, Guillermo Izquierdo, Helmut Butzkueven, (unknown), (unknown)	4
18	Clinical Efficacy of BG-12 (Dimethyl Fumarate) for Relapsing–Remitting Multiple Sclerosis (RRMS) According to Prior Therapy: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies (P07.128) 2013 ·Neurology ·Michael Hutchinson, Ralf Gold, Robert J. Fox, Eva Havrdová, Gavin Giovannoni, Annie Zhang, Christophe Hotermans, (unknown), Katherine Dawson, Amit Bar‐Or	3
19	Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS 2012 ·Journal of the Neurological Sciences ·Laura J. Balcer, Steven Galetta, Chris H. Polman, Eric Eggenberger, Peter A. Calabresi, Annie Zhang, James Scanlon, Robert Hyde	47
20	Corporate image, loyalty, and commitment in the consumer travel industry 2011 ·Journal of Marketing Management ·James Richard, Annie Zhang	129

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact